Sam Chun Dang Pharm countered that "the sale of the largest shareholder is groundless"

Reporter Kim Jisun / approved : 2024-04-05 03:07:22
  • -
  • +
  • 인쇄

 

[Alpha Biz= Reporter Kim Jisun] Sam Chun Dang Pharm's share price plunged recently due to unfavorable rumors circulating in the market, suggesting a legal response to the distributor.

According to the Korea Exchange on the 4th, Sam Chun Dang Pharm closed at 111,400 won on the KOSDAQ market. The stock price plunged 20% in three trading days from KRW 140,700 on the 1st.

There is a rumor that spread in the market behind the plunge in Sam Chun Dang Pharm's stock price. It is a negative rumor related to the core valuation business, the Ilia biosimilar, and the sale of the largest shareholder.

The largest shareholder of Sam Chun Dang Pharm is Sohwa (30.7%). Yoon Dae-in, chairman of Samcheondang Pharmaceutical, holds 6.9%. The largest shareholder of unlisted companies is Chairman Yoon (72.22%).

 

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

어플

주요기사

Bomb Threats Target Major Korean Companies Including Samsung Electronics2025.12.19
FSS Raises Consumer Alert to “Warning” Over Secondary Scams Linked to Coupang Data Breach2025.12.19
Final U.S. Defense Authorization Bill Omits Provisions Supporting South Korea-Japan Shipbuilding Cooperation2025.12.19
Controversy Surrounds KT’s Former Outside Director Cho Seung-ah Amid Dual Directorship Issue2025.12.19
Samsung Securities Lowers LG Energy Solution Target Price to KRW 480,000 Amid Contract Cancellations2025.12.19
뉴스댓글 >

건강이 보이는 대표 K Medical 뉴스

HEADLINE

PHOTO

많이 본 기사